Clinical Actionability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical actionability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Actionability Today - Breaking & Trending Today

Most molecular-targeted cancer therapies show no 'substantial' benefit at approval

Most molecular-targeted cancer therapies show no 'substantial' benefit at approval
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Mindy Valcarcel , Bymatthew Shinkle , Ariadna Tibau , Harvard Medical School , European Society For Medical Oncology , European Society , Medical Oncology , Clinical Actionability , Molecular Targets , Clinical Benefit , Clinical Benefit Scale ,

Forget lung, breast or prostate cancer: why tumour naming needs to change

The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. ....

United States , France General , Fabrizio Villa Getty , Gustave Roussy , European Society Of Medical Oncology , National Precision Medicine Cancer Center , American Society Of Clinical Oncology , Drug Administration , American Society , Clinical Oncology , European Society , Medical Oncology , Clinical Benefit Scale , Clinical Actionability , Medicine Cancer Center ,

Nearly half of oncology drugs approved since 1998 are precision therapies

Nearly half of oncology drugs approved since 1998 are precision therapies
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Sarahp Suehnholz , Debyani Chakravarty , Drug Administration , Memorial Sloan Kettering Cancer Center , Expanding Landscape , Clinical Actionability , Cancer Discovery ,

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations. ....

Comunidad Autonoma De Cataluna , France General , Cordeliers Research Center , French Medicine Genomic Program , International Liver Cancer Association Conference , Liver Cancer Association , Wendy Limousin , Sorbonne Universit , Medicine Genomic Program , Clinic Liver Cancer , Clinical Actionability , Molecular Targets , Hepatocellular Carcinoma ,

Should Every Cancer Patient Have Next-Generation Sequencing?

Patients with cancer are increasingly having tumor DNA sequenced to identify disease markers and potential targets, but some investigators question whether every cancer patient can benefit. ....

United States , Dana Farber Cancer Institute , Nilay Sethi , Dana Farber Sethi , Ramon Colomer , Harvard Medical School , Contra Cancer Foundation , European Regional Development Fund , European Society For Medical Oncology , Health Institute , Human Genome Project , Medscape Medical , Universidad Aut , Hospital Universitario La Princesa , European Society , Medical Oncology , Clinical Actionability , Medscape Medical News , Published June ,